Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
|
31548343 |
2020 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MET c-Cbl binding site mutations constitute about 2 % of MET exon 14 alterations in lung cancer.
|
31809977 |
2020 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
|
31698509 |
2020 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplification of the de novo MET gene was identified in 47 patients with lung cancer.
|
30554986 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The presence of MET exon 14 mutations in minor histological types of lung cancers urge to extend screening scope of this mutation in lung cancer and treatment response evaluation in clinical trials.
|
31369639 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
KRAS mutations may act as a resistance mechanism to MET inhibition in MET dependent lung cancer.
|
31200822 |
2019 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A significant positive correlation between MET and PD-L1 expression in lung cancer was determined in an analysis based on The Cancer Genome Atlas (TCGA) and in an immunohistochemistry study.
|
31480591 |
2019 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Sarcomatoid transformation is a type of lung cancer histologic evolution with a poor prognosis and a high proportion of cases with aberrant MET activation and PD-L1 expression.
|
31561203 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we report the dysregulation of mutant MET originally found in a lung cancer patient with Val370 to Asp370 (V370D) replacement located in the extracellular SEMA domain.
|
31342590 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
[Corrigendum] AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
|
30542697 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore EGFR and MET may be attractive targets for lung cancer therapy.
|
31323446 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found a panel of benzisoselenazolones (BISAs) obtained by introducing isothiourea, tetramethylthiourea and heterocyclic groups into the C-ring of Ebselen, including <b>7a</b>, <b>7b</b>, <b>8a</b>, <b>8b</b> and <b>12c</b> (with IC<sub>50</sub> values of less than 20 μM in MET gene amplified lung cancer cell line EBC-1), exhibited more potent antitumour activity than Ebselen by cell growth assay combined with in vitro biochemical assays.
|
31137515 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
A 1-MET increase and categories of moderate and high CRF were associated with 10%, 47% and 65% reduction in lung cancer incidence (p=0.002), and 13%, 58% and 76% reduction in cancer mortality (p=0.002), respectively.
|
30803499 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
It was revealed that LINC00887 interacts with several microRNAs (miRs), which regulates downstream genes such as fibronectin 1, MET proto‑oncogene, receptor tyrosine kinase and mothers against decapentaplegic homolog 4, which are associated with the spread of lung cancer.
|
31322230 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MNNG HOS Transforming gene (MET) amplification and MET exon 14 (METex14) alterations in lung cancers affect sensitivity to MET proto-oncogene, receptor tyrosine kinase (MET [also known by the alias hepatocyte growth factor receptor]) inhibitors.
|
31228623 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
|
31227004 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have already demonstrated an implication of MET and RON genes in brain metastases from lung cancer.
|
30813513 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study provides preclinical evidences that combination therapy of CsA and crizotinib is a promising approach for targeted treatment of MET-amplified lung cancer patients.
|
30879923 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erratum: Stella, G.M. et al. Brain Metastases from Lung Cancer: Is MET an Actionable Target? <i>Cancers</i> 2019, <i>11</i>, 271.
|
31083323 |
2019 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The cytotoxicity assay results revealed that c‑MET‑CAR‑NK cells exhibited more specific cytotoxicity for HepG2 cells with high c‑MET expression compared with the lung cancer cell line H1299, which has low levels of c‑MET expression.
|
31524233 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among former smokers, 1-MET increase and categories of moderate and high cardiorespiratory fitness were associated with 13% (p=0.016), 51%, and 77% (p-trend=0.015) reductions in lung cancer incidence, respectively.
|
31564605 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies.
|
31104010 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>KRAS</i> mutation is a recurrent mechanism of primary and secondary resistance to MET TKIs in <i>MET</i>ex14 lung cancers.
|
30352902 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, GM-CSF combined with MET PTX exerted a synergistic anti-tumor effect against lung cancer in a mouse model through an antiangiogenic activity and inducing dendritic cells maturation without exerting pronounced adverse effects.
|
29435154 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silencing of Long Noncoding RNA <i>MIR22HG</i> Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer.
|
29669758 |
2018 |